NCM
HARP

Nantahala Capital Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Nantahala Capital Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-47,547
Closed -$3.59M – 141
2021
Q4 		$3.59M Buy
47,547
+5,699
+14% +$389K 0.13% 89
2021
Q3 		$3.31M Sell
41,848
-2,477
-6% -$249K 0.1% 92
2021
Q2 		$6.15M Sell
44,325
-956
-2% -$182K 0.17% 86
2021
Q1 		$9.47M Buy
+45,281
New +$9.08M 0.28% 69

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nantahala Capital Management's HARP Position: Q1 2022 in Review

Nantahala Capital Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2022, closing a stake of 47,547 shares — an estimated $3.59M sold.

Nantahala Capital Management first reported a position in HARP in Q1 2021 and held it in 4 quarters. The position peaked at $9.47M in Q1 2021. 79 funds tracked by Wall St. Rank hold HARP as of Q1 2022.

  • Nantahala Capital Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 47,547 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.59M.
  • Nantahala Capital Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Nantahala Capital Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $9.47M in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Nantahala Capital Management's 13F filing for Q1 2022, filed 13 May 2022.